US20190292176A1 - Bicyclic heteroaryl substituted compounds - Google Patents

Bicyclic heteroaryl substituted compounds Download PDF

Info

Publication number
US20190292176A1
US20190292176A1 US16/317,248 US201716317248A US2019292176A1 US 20190292176 A1 US20190292176 A1 US 20190292176A1 US 201716317248 A US201716317248 A US 201716317248A US 2019292176 A1 US2019292176 A1 US 2019292176A1
Authority
US
United States
Prior art keywords
och
methylquinoxalin
methoxy
thiazol
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/317,248
Other languages
English (en)
Inventor
Xiaojun Zhang
Eldon Scott Priestley
J. Alex BATES
Oz Scott Halpern
Samuel Kaye REZNIK
Jeremy M. Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US16/317,248 priority Critical patent/US20190292176A1/en
Publication of US20190292176A1 publication Critical patent/US20190292176A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention generally relates to bicyclic heteroaryl substituted compounds useful as inhibitors of platelet aggregation.
  • bicyclic heteroaryl substituted compounds useful as inhibitors of platelet aggregation.
  • compositions comprising such compounds, and methods of their use.
  • the invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful in preventing or treating thromboembolic disorders.
  • Thromboembolic diseases remain the leading cause of death in developed countries despite the availability of anticoagulants such as warfarin (COUMADIN®), heparin, low molecular weight heparins (LMWH), synthetic pentasaccharides, and antiplatelet agents such as aspirin and clopidogrel (PLAVIX®).
  • anticoagulants such as warfarin (COUMADIN®), heparin, low molecular weight heparins (LMWH), synthetic pentasaccharides, and antiplatelet agents such as aspirin and clopidogrel (PLAVIX®).
  • Alpha-thrombin is the most potent known activator of platelet aggregation and degranulation. Activation of platelets is causally involved in atherothrombotic vascular occlusions.
  • Thrombin activates platelets by cleaving G-protein coupled receptors termed protease activated receptors (PARs).
  • PARs provide their own cryptic ligand present in the N-terminal extracellular domain that is unmasked by proteolytic cleavage, with subsequent intramolecular binding to the receptor to induce signaling (tethered ligand mechanism; Coughlin, S. R., Nature, 407:258-264 (2000)).
  • Synthetic peptides that mimic the sequence of the newly formed N-terminus upon proteolytic activation can induce signaling independent of receptor cleavage.
  • Platelets are a key player in atherothrombotic events. Human platelets express at least two thrombin receptors, commonly referred to as PAR1 and PAR4. Inhibitors of PAR1 have been investigated extensively, and several compounds, including vorapaxar and atopaxar have advanced into late stage clinical trials. Recently, in the TRACER phase III trial in ACS patients, vorapaxar did not significantly reduce cardiovascular events, but significantly increased the risk of major bleeding (Tricoci, P. et al., N. Eng. J. Med., 366(1):20-33 (2012). Thus, there remains a need to discover new antiplatelet agents with increased efficacy and reduced bleeding side effects.
  • Compound 58 is also referred to as YD-3 in Wu, C-C. et al., “Selective Inhibition of Protease-activated Receptor 4-dependent Platelet Activation by YD-3 ”, Thromb. Haemost., 87:1026-1033 (2002). Also, see Chen, H. S. et al., “Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives”, Bioorg. Med. Chem., 16:1262-1278 (2008).
  • EP1166785 A1 and EP0667345 disclose various pyrazole derivatives which are useful as inhibitors of platelet aggregation.
  • potent compounds that have activity as PAR4 inhibitors. These compounds are provided to be useful as pharmaceuticals with desirable potency, stability, bioavailability, therapeutic index, and toxicity values that are important to their drugability.
  • bicyclic heteroaryl substituted compounds in accordance with the present invention are PAR4 antagonists which inhibit platelet aggregation in gamma-thrombin induced platelet aggregation assays.
  • the present invention provides bicyclic heteroaryl substituted compounds that are PAR4 antagonists and are useful as selective inhibitors of platelet aggregation, including stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides processes and intermediates for making the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides a method for the treatment or prophylaxis of thromboembolic disorders comprising administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for use in therapy.
  • the present invention also provides the use of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the manufacture of a medicament for the treatment or prophylaxis of a thromboembolic disorder.
  • the first aspect of the present invention provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII):
  • R 1 is F, Cl, —OH, C 1-4 alkyl, C 1-4 fluoroalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 3-7 fluorocycloalkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy, C 2-4 hydroxyalkoxy, C 3-6 cycloalkoxy, (C 1-3 alkoxy)-(C 1-3 alkylene), (C 1-3 alkoxy)-(C 1-3 fluoroalkylene), (C 1-3 deuteroalkoxy)-(C 1-3 deuteroalkylene), (C 1-3 fluoroalkoxy)-(C 1-3 alkylene), (C 1-3 fluoroalkoxy)-(C 1-3 fluoroalkylene), —(CH 2 ) 1-3 O(phenyl), —(CH 2 ) 1-3 NR a R a , —C(O)O(C 1-6 alkyl),
  • R 2 is independently H, F, Cl, Br, —OH, —CN, C 1-4 alkyl, C 1-4 fluoroalkyl, C 1-4 hydroxyalkyl, C 1-3 aminoalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 3-7 fluorocycloalkyl, C 1-6 alkoxy, C 1-3 fluoroalkoxy, C 1-3 alkylthio, C 1-3 fluoroalkylthio, (C 1-3 alkoxy)-(C 1-3 alkylene), (C 1-3 fluoroalkoxy)-(C 1-3 alkylene), —C(O)NH 2 , —C(O)NH(C 1-6 alkyl), —C(O)N(C 1-6 alkyl) 2 , —C(O)O(C 1-6 alkyl), —C(O)NH(CH 2 CH 2 O(C 1-3 alkyl)),
  • R 3 is a bicyclic group selected from indolyl, benzofuranyl, benzo[b]thiophenyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]thiazolyl, imidazol[1,2-a]pyridinyl, thiazolo[4,5-b]pyridinyl, thiazolo[4,5-c]pyridinyl, thiazolo[5,4-b]pyridinyl, thiazolo[5,4-c]pyridinyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, 4,5,6,7-tetrahydrobenzofuranyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl, 5,6,7,8-tetrahydro-4H-cyclohepta[d]thiazolyl, 5,6-dihydro-4H-cyclopenta[
  • R 3a at each occurrence, is independently:
  • R 4 is H, F, Cl, or —CH 3 ;
  • R a at each occurrence, is independently H, C 1-4 alkyl, or C 1-4 fluoroalkyl
  • R c at each occurrence, is independently C 1-3 alkyl or C 1-3 hydroxyalkyl, or two R c along with the nitrogen atom to which they are attached form a heterocyclyl or bicyclic heterocyclyl;
  • R d is independently C 1-6 alkyl, C 1-4 fluoroalkyl, C 1-6 hydroxyalkyl, (C 1-4 alkoxy)-(C 1-3 alkylene), (C 1-2 fluoroalkoxy)-(C 1-2 alkylene), (C 3-6 cycloalkyl)-(C 0-2 alkylene), aryl(C 1-2 alkylene), heteroaryl(C 1-2 alkylene), aryloxy-(C 1-2 alkylene), aryl-CH 2 O—(C 1-2 alkylene), or heteroaryloxy-(C 1-2 alkylene); and
  • n zero, 1, or 2.
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein
  • R 1 is —OH, C 1-2 alkyl, —CHFCH 3 , —CH ⁇ CH 2 , C 1-3 alkoxy, C 1-2 fluoroalkoxy, —OCH 2 CH 2 OH, —CH 2 O(C 1-2 alkyl), —CD 2 OCD 3 , —CH 2 OCHF 2 , —CF 2 OCH 3 , —CH 2 O(phenyl), —CH(CH 3 )OCH 3 , —NH(CH 3 ), —N(CH 3 ) 2 , —CH 2 N(CH 3 ) 2 , —C(O)NH 2 , —C(O)NH(CH 3 ), —C(O)N(CH 3 ) 2 , —C(O)NH(CH 2 CH 2 OH), —C(O)OCH 3 , —CH(CH 3 )OCH 3 , cyclopropyl, furanyl, or —O(cyclopropyl);
  • R 2 is independently H, F, Cl, —CN, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , —OCF 3 , —CH 2 OH, —CH 2 CH 2 OH, —CH(CH 3 )OH, —C(CH 3 ) 2 OH, —CH(OH)CH 2 OH, —CH 2 NH 2 , —C(O)NH 2 , —C(O)N(CH 3 ) 2 , —C(O)(piperidinyl), —C(O)OCH 3 , —C(O)NH(CH 2 CH 2 OCH 3 ), —CH(OH)(cyclopropyl), —CH(OH)(phenyl), —CH ⁇ CH 2 , —C(CH 3 ) ⁇ CH 2 , or —C ⁇ CH;
  • R 3 is:
  • R 3a at each occurrence, is independently:
  • One embodiment provides at least one compound of Formulas (I), (II), (III) or (IV) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect. Included in this embodiment are compounds in which R 3 is:
  • R 3a is defined in the first aspect. Also included in this embodiment are compounds in which R 4 is H, F, or —CH 3 .
  • One embodiment provides at least one compound of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formulas (I) or (II) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (II) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (III) or a salt thereof, wherein R 1 , R 2 , R 3 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (IV) or a salt thereof, wherein R 1 , R 2 , R 3 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (V) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (VI) or a salt thereof, wherein R 1 , R 2 , R 3 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (VII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , and n are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect. Included in this embodiment are compounds in which R 3 is:
  • R 3a is defined in the first aspect. Also included in this embodiment are compounds in which R 4 is H, F, or —CH 3 .
  • One embodiment provides at least one compound of Formulas (I) or (II) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , and n are defined in the first aspect. Included in this embodiment are compounds in which R 3 is:
  • R 3a is defined in the first aspect.
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), or (VIII) or a salt thereof, wherein R 3 is:
  • R m is H or Cl
  • R k is H or F
  • R 1 , R 2 , R 3a , R 4 , and n are defined in the first aspect. Included in this embodiment are compounds of Formula (I).
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 3 is:
  • R 1 , R 2 , R 3a , R 4 , and n are defined in the first aspect. Included in this embodiment are compounds of Formula (I).
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 is —OH, C 1-2 alkyl, —CHFCH 3 , —CH ⁇ CH 2 , C 1-3 alkoxy, C 1-2 fluoroalkoxy, —OCH 2 CH 2 OH, —CH 2 O(C 1-2 alkyl), —CD 2 OCD 3 , —CH 2 OCHF 2 , —CF 2 OCH 3 , —CH 2 O(phenyl), —CH(CH 3 )OCH 3 , —NH(CH 3 ), —N(CH 3 ) 2 , —CH 2 N(CH 3 ) 2 , —C(O)NH 2 , —C(O)NH(CH 3 ), —C(O)N(CH 3 ) 2 , —C(O)NH(CH 2 CH 2 OH), —C
  • R 2 at each occurrence, is independently H, F, Cl, —CN, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , —OCF 3 , —CH 2 OH, —CH 2 CH 2 OH, —CH(CH 3 )OH, —C(CH 3 ) 2 OH, —CH(OH)CH 2 OH, —CH 2 NH 2 , —C(O)NH 2 , —C(O)N(CH 3 ) 2 , —C(O)(piperidinyl), —C(O)OCH 3 , —C(O)NH(CH 2 CH 2 OCH 3 ), —CH(OH)(cyclopropyl), —CH(OH)(phenyl),
  • One embodiment provides at least one compound of Formula (I), (II), (V), and (VII) or a salt thereof, wherein R 4 is H, F, or —CH 3 ; and R 1 , R 2 , R 3 , and n are defined in the first aspect. Included in this embodiment are compounds in which R 4 is H and F. Also included in this compounds in which R 4 is H.
  • R 3a at each occurrence, is independently, (i) F, Cl, —CN, —OH, —CH 3 , —CF 3 , —CHFC(CH 3 ) 3 , cyclopropyl, —CH 2 OH, —CD 2 OH, —CH 2 CH 2 OH, —CH(OH)CH 3 , —C(CH 3 ) 2 OH, —CH(OH)C(CH 3 ) 3 , —CD(OH)C(CH 3 ) 3 , —CH(OH)CF 3 , —CH(OH)CH 2 CF 3 , —CH(OH)(cyclopropyl), —CH(OH)(methylcyclopropyl), —CH(OH)(trifluoromethylcyclopropyl), —CH(OH)(cyclopropyl), —CH(OH)(cyclopropyl), —CH(OH)(methylcyclopropyl), —CH(OH)(trifluoromethylcyclo
  • R 3 is substituted with one R 3a selected from (i) F, Cl, —CN, —OH, —CH 3 , —CF 3 , —CHFC(CH 3 ) 3 , cyclopropyl, —CH 2 OH, —CD 2 OH, —CH 2 CH 2 OH, —CH(OH)CH 3 , —C(CH 3 ) 2 OH, —CH(OH)C(CH 3 ) 3 , —CD(OH)C(CH 3 ) 3 , —CH(OH)CF 3 , —CH(OH)CH 2 CF 3 , —CH(OH)(cyclopropyl), —CH(OH)(methylcyclopropyl), —CH(OH)(trifluoromethylcyclopropyl), —CH(OH)(cyclopropyl), —CH(OH)(cyclopropyl), —CH(OH)(methylcyclopropyl), —CH(OH)(trifluoromethylcycl
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , R a , R b , R d , and n are defined in the first aspect with the proviso that at least one R 3a is F, Cl, —CN, —OH, C 1-3 alkyl, C 1-6 fluoroalkyl, C 1-6 hydroxyalkyl, C 1-6 hydroxy-deuteroalkyl, C 1-6 hydroxy-fluoroalkyl, C 1-6 alkoxy, C 1-3 fluoroalkoxy, C 3-6 cycloalkyl, C 3-6 fluorocycloalkyl, 3- to 6-membered heterocyclyl, —CH(OH)R y wherein R y is C 3-6 cycloalkyl, aryl, heteroaryl, or 3- to
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , R a , R b , R d , and n are defined in the first aspect with the proviso that at least one R 3a is —CH(OH)CR h R i R j wherein R h and R i are independently H, F, C 1-4 alkyl, C 1-3 alkoxy, or taken together with the carbon atom to which they are attached, form C 3-8 cycloalkyl or 4- to 7-membered heterocyclyl ring; and R j is H, C 1-6 alkyl, C 1-5 fluoroalkyl, (C 1-3 alkoxy)-(C 1-3 alkylene), C 3-8 cycloalkyl, C 3-8 heterocyclyl, aryl, or heteroaryl
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , R a , R b , R d , and n are defined in the first aspect with the proviso that at least one R 3a is —O(CH 2 ) 1-4 NR a S(O) 2 (C 1-3 alkyl) or —O(CH 2 ) 1-4 NR a S(O) 2 R w , wherein R w is aryl or heteroaryl, each substituted with zero to 2 substituents independently selected from F, Cl, cyano, C 1-3 alkyl, C 1-3 alkoxy, —OCF 3 , —OCHF 2 , and C 1-3 fluoroalkyl; and p is 1, 2, or 3. Included in this embodiment are compounds of Formulas (I), (II
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , R a , R b , R d , and n are defined in the first aspect with the proviso that at least one R 3a is —O(CH 2 ) 1-4 OC(O)NR a R x , —OCH(R d )(CH 2 ) 1-3 OC(O)NR a R x , —OCR d R d (CH 2 ) 1-3 OC(O)NR a R x , —O(CH 2 ) 1-3 CH(R d )OC(O)NR a R x , —O(CH 2 ) 1-3 CR d R d OC(O)NR a R x , —OCH(R d
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , and n are defined in the first aspect with the proviso that at least one R 3a is F, Cl, —CN, —OH, —CH 3 , —CF 3 , —CHFC(CH 3 ) 3 , cyclopropyl, —CH 2 OH, —CD 2 OH, —CH 2 CH 2 OH, —CH(OH)CH 3 , —C(CH 3 ) 2 OH, —CH(OH)C(CH 3 ) 3 , —CD(OH)C(CH 3 ) 3 , —CH(OH)CF 3 , —CH(OH)CH 2 CF 3 , —CH(OH)(cyclopropyl), —CH(OH)(methylcycloprop
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , and n are defined in the first aspect with the proviso that at least one R 3a is —OCH 3 , —OCH 2 CH 3 , —OCH(CH 3 ) 2 , —OCF 3 , —OCHF 2 , —OCH 2 (phenyl), —OCH 2 (thiazolyl), —OCH 2 (oxazolidinonyl), —OCH 2 (amino isoxazolyl), —OCH 2 (imidazolyl substituted with phenyl), —OCH 2 CH 2 OH, —OCH 2 CH(CH 3 )OH, —OCH 2 CH 2 OCH 3 , —OCH(CH 3 )CH 2 OH, —OC
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , and n are defined in the first aspect with the proviso that at least one R 3a is —C(O)OH, —C(O)OCH 3 , or —C(O)OC(CH 3 ) 3 ; and p is 1, 2, or 3. Included in this embodiment are compounds of Formulas (I), (II), (III), or (IV).
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , and n are defined in the first aspect with the proviso that at least one R 3a is —NHC(O)OCH 3 , —NHC(O)OC(CH 3 ) 3 , —NHC(O)OCH 2 (phenyl), —NHC(O)OCH 2 (tetrahydrofuranyl), or —NHC(O)O(tetrahydropyranyl); and p is 1, 2, or 3. Included in this embodiment are compounds of Formulas (I), (II), (III), or (IV).
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , and n are defined in the first aspect with the proviso that at least one R 3a is —OCH 2 CH 2 NHC(O)OCH 3 , —OCH 2 CH 2 NHC(O)O(tetrahydropyranyl), —OCH 2 CH 2 NHC(O)OCH 2 (phenyl), —OCH 2 CH 2 NHC(O)O(methoxyphenyl), —OCH 2 CH 2 NHC(O)O(tetrahydrofuranyl), —OCH 2 CH 2 NHC(O)OCH 2 (tetrahydrofuranyl), —OCH 2 CH 2 NHC(O)NH(pyridinyl), —OCH 2 CH 2 N(CH 3 )C(O
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , and n are defined in the first aspect with the proviso that at least one R 3a is —OCH 2 CH 2 NHS(O) 2 CH 3 or —OCH 2 CH 2 NHS(O) 2 R w wherein R w is phenyl or pyridinyl, each substituted with zero to 2 substituents independently selected from F, Cl, and —CH 3 ; and p is 1, 2, or 3. Included in this embodiment are compounds of Formulas (I), (II), (III), or (IV).
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 1 , R 2 , R 3 , R 3a , R 4 , and n are defined in the first aspect with the proviso that at least one R 3a is —OCH 2 CH 2 OC(O)NHR z , —OCH(CH 3 )CH 2 OC(O)NHR z , —OCH 2 CH(CH 3 )OC(O)NHR z , —OCH(CH 3 )CH(CH 3 )(CH 2 ) 0-2 OC(O)NHR z , —OCH 2 CH(CH 2 O(isobutyl))(CH 2 ) 0-2 OC(O)NHR z , —OCH 2 CH(CH 2 CH 3 )OC(O)NHR z , —OCH 2 CH(CH 2 O
  • One embodiment provides at least one compound of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII) or a salt thereof, wherein R 3 is substituted with zero to 1 R 3a . Included in this embodiment are compounds in which R 3 is unsubstituted.
  • One embodiment provides at least one compound of Formula (I) or a salt thereof, wherein R 1 is —OCH 3 , —OCHF 2 , —OCH 2 CH 3 , or —CH 2 OCH 3 ; R 2 , at each occurrence, is independently H, F, Cl, —CN, —CH 3 , —OCH 3 , or —CH 2 OH; and
  • R 3 is:
  • R 4 , R 3a , and p are defined in the first aspect.
  • One embodiment provides at least one compound of Formula (II) or a salt thereof, wherein R 1 is —OH, —OCH 3 , —OCH 2 CH 3 , —OCHF 2 , —OCH 2 CHF 2 , —CH 2 OCH 3 , or —NH(CH 3 ); R 2 , at each occurrence, is independently F, Cl, —CN, —CH 3 , —CH 2 OH, —CH 2 F, —CHF 2 , or —OCH 3 ;
  • R 3 is:
  • R 3a at each occurrence, is independently F, Cl, —CH 3 , —OCH 3 , —CH(OH)(trifluoromethylcyclobutyl), —OCH 2 CH(CH 3 )OC(O)NHR z , or —OCH(CH 3 )CH(CH 3 )OC(O)NHR z , wherein R z is pyridinyl, pyrimidinyl, or benzo[d]oxazolonyl, each substituted with zero to 2 substituents independently selected from F, —OH, —CN, —CH 3 , —CF 3 , —CH 2 OH, —CH 2 CH 2 OH, —OCH 2 CH 2 OH, —OCH 3 , —CH 2 CH(CH 3 )OH, and —OCH 2 CH 2 C(CH 3 ) 2 OH; and R 4 and p are defined in the first aspect.
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is indolyl. Included in this embodiment is a compound of Formula (I) selected from 2-(difluoromethoxy)-5-(1H-indol-2-yl)-7-methylquinoxaline (5).
  • One embodiment provides compounds selected from one of the examples, more preferably, Examples 1 to 837, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof.
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is benzofuranyl. Included in this embodiment is a compound of Formulas (I), (II), (III), or (IV) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is benzo[b]thiophenyl. Included in this embodiment is a compound of Formula (I) selected from
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is benzo[d]imidazolyl. Included in this embodiment is a compound of Formula (I) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is benzo[d]oxazolyl. Included in this embodiment is a compound of Formula (I) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is benzo[d]thiazolyl. Included in this embodiment is a compound of Formula (I) to (III) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is imidazol[1,2-a]pyridinyl. Included in this embodiment is a compound of Formula (I) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is thiazolo[4,5-b]pyridinyl. Included in this embodiment is a compound of Formula (I) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is thiazolo[5,4-b]pyridinyl. Included in this embodiment is a compound of Formula (I) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is 4,5,6,7-tetrahydrobenzo[d]thiazolyl. Included in this embodiment is a compound of Formula (I) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is 4,5,6,7-tetrahydrobenzofuranyl. Included in this embodiment is a compound of Formula (I) selected from: tert-butyl (2-(2-(difluoromethoxy)-7-methylquinoxalin-5-yl)-4,5,6,7-tetrahydrobenzofuran-4-yl) carbamate (25).
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is 6,7-tetrahydrothiazolo[5,4-c]pyridinyl.
  • R 3 is 6,7-tetrahydrothiazolo[5,4-c]pyridinyl.
  • a compound of Formula (I) selected from: tert-butyl 2-(2-(difluoromethoxy)-7-methylquinoxalin-5-yl)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (11) and methyl 2-(2-(difluoromethoxy)-7-methylquinoxalin-5-yl)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (62).
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is 5,6,7,8-tetrahydro-4H-cyclohepta[d]thiazolyl. Included in this embodiment is a compound of Formula (I) selected from:
  • One embodiment provides compounds of Formulas (I), (II), (III), or (IV) or a salt thereof, wherein R 3 is 5,6-dihydro-4H-cyclopenta[d]thiazolyl. Included in this embodiment is a compound of Formula (I) selected from:
  • references made in the singular may also include the plural.
  • references made in the singular may also include the plural.
  • “a” and “an” may refer to either one, or one or more.
  • a compound of Formula (I) includes a compound of Formula (I) and two or more compounds of Formula (I).
  • any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
  • halo and halogen, as used herein, refer to F, Cl, Br, and I.
  • cyano refers to the group —CN.
  • amino refers to the group —NH 2 .
  • alkyl refers to both branched and straight-chain saturated aliphatic hydrocarbon groups containing, for example, from 1 to 12 carbon atoms, from 1 to 6 carbon atoms, and from 1 to 4 carbon atoms.
  • alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl.
  • Me methyl
  • Et ethyl
  • propyl e.g., n-propyl and i-propyl
  • butyl e.g., n-butyl, i-butyl, sec-butyl, and t-butyl
  • pentyl e.g., n-pentyl
  • C 1-4 alkyl denotes straight and branched chain alkyl groups with one to four carbon atoms.
  • fluoroalkyl as used herein is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more fluorine atoms.
  • C 1-4 fluoroalkyl is intended to include C 1 , C 2 , C 3 , and C 4 alkyl groups substituted with one or more fluorine atoms.
  • Representative examples of fluoroalkyl groups include, but are not limited to, —CF 3 and —CH 2 CF 3 .
  • aminoalkyl as used herein is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more amino groups.
  • C 1-4 aminoalkyl is intended to include C 1 , C 2 , C 3 , and C 4 alkyl groups substituted with one or more amino groups.
  • Representative examples of aminoalkyl groups include, but are not limited to, —CH 2 NH 2 , —CH 2 CH 2 NH 2 , and —CH 2 CH(NH 2 )CH 3 .
  • hydroxyalkyl includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups.
  • hydroxyalkyl includes —CH 2 OH, —CH 2 CH 2 OH, and C 1-4 hydroxyalkyl.
  • hydroxy-deuteroalkyl includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups and one or more deuterium atoms.
  • Representative examples of hydroxy-deuteroalkyl groups include, but are not limited to, —CD 2 OH and —CH(CD 3 ) 2 OH.
  • hydroxy-fluoroalkyl includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups and one or more fluorine atoms.
  • Representative examples of hydroxy-fluoroalkyl groups include, but are not limited to, —CF 2 OH and —CF 2 CH 2 OH.
  • alkylene refers to a bivalent alkyl radical having the general formula —(CH 2 ) n —, where n is 1 to 10.
  • Non-limiting examples include methylene, dimethylene, trimethylene, tetramethylene, pentamethylene, and hexamethylene.
  • C 1-6 alkylene denotes straight and branched chain alkylene groups with one to six carbon atoms.
  • C 0-4 alkylene denotes a bond and straight and branched chain alkylene groups with one to four carbon atoms.
  • deuteroalkylene refers to an alkylene group in which one or more hydrogen atoms have been replaced with deuterium atoms.
  • C 1-6 deuteroalkylene denotes straight and branched chain deuteroalkylene groups with one to six carbon atoms.
  • fluoroalkylene refers to an alkylene group substituted with one or more fluorine atoms.
  • C 1-6 fluoroalkylene denotes straight and branched chain fluoroalkylene groups with one to six carbon atoms.
  • alkenyl refers to a straight or branched chain hydrocarbon radical containing from 2 to 12 carbon atoms and at least one carbon-carbon double bond. Exemplary such groups include ethenyl or allyl.
  • C 2-6 alkenyl denotes straight and branched chain alkenyl groups with two to six carbon atoms.
  • alkynyl refers to a straight or branched chain hydrocarbon radical containing from 2 to 12 carbon atoms and at least one carbon to carbon triple bond. Exemplary such groups include ethynyl.
  • C 2-6 alkynyl denotes straight and branched chain alkynyl groups with two to six carbon atoms.
  • cycloalkyl refers to a group derived from a non-aromatic monocyclic or polycyclic hydrocarbon molecule by removal of one hydrogen atom from a saturated ring carbon atom.
  • Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl.
  • the subscript defines with more specificity the number of carbon atoms that a particular cycloalkyl group may contain.
  • C 3-6 cycloalkyl denotes cycloalkyl groups with three to six carbon atoms.
  • fluorocycloalkyl refers to a cycloalkyl group in which one or more hydrogen atoms are replaced by fluoro group(s).
  • hydroxycycloalkyl refers to a cycloalkyl group in which one or more hydrogen atoms are replaced by hydroxyl group(s).
  • alkoxy refers to an alkyl group attached to the parent molecular moiety through an oxygen atom, for example, methoxy group (—OCH 3 ).
  • —OCH 3 methoxy group
  • C 1-3 alkoxy denotes alkoxy groups with one to three carbon atoms.
  • fluoroalkoxy and “—O(fluoroalkyl)” represent a fluoroalkyl group as defined above attached through an oxygen linkage (—O—).
  • C 1-4 fluoroalkoxy is intended to include C 1 , C 2 , C 3 , and C 4 fluoroalkoxy groups.
  • hydroxyalkoxy represent a hydroxyalkyl group as defined above attached through an oxygen linkage (—O—).
  • C 1-4 hydroxyalkoxy is intended to include C 1 , C 2 , C 3 , and C 4 hydroxyalkoxy groups.
  • hydroxy-fluoroalkoxy represent a hydroxy-fluoroalkyl group as defined above attached through an oxygen linkage (—O—).
  • C 1-4 hydroxy-fluoroalkoxy is intended to include C 1 , C 2 , C 3 , and C 4 hydroxy-fluoroalkoxy groups.
  • cycloalkoxy refers to a cycloalkyl group attached to the parent molecular moiety through an oxygen atom, for example, cyclopropoxy group (—O(cyclopropyl)).
  • alkoxyalkoxy refers to an alkoxy group attached through an alkoxy group to the patent molecular moiety.
  • (C 1-3 alkoxy)-(C 1-6 alkoxy) denotes a C 1-3 alkoxy group attached through a C 1-6 alkoxy group to the parent molecular moiety.
  • alkoxyalkylene refers to an alkoxy group attached through an alkylene group to the patent molecular moiety.
  • (C 1-3 alkoxy)-(C 1-3 alkylene) denotes a C 1-3 alkoxy group attached through a C 1-3 alkylene to the parent molecular moiety.
  • fluoroalkoxyalkylene refers to a fluoroalkoxy group attached through an alkylene group.
  • (C 1-2 fluoroalkoxy)-(C 1-2 alkylene) denotes a C 1-2 fluoroalkoxy group attached through a C 1-2 alkylene to the parent molecular moiety.
  • alkoxy-fluoroalkylene refers to an alkoxy group attached through a fluoroalkylene group to the patent molecular moiety.
  • (C 1-3 alkoxy)-(C 1-3 fluoroalkylene) denotes a C 1-3 alkoxy group attached through a C 1-3 fluoroalkylene to the parent molecular moiety.
  • deuteroalkoxy-deuteroalkylene refers to a deuteroalkoxy group attached through a deuteroalkylene group to the patent molecular moiety.
  • (C 1-3 deuteroalkoxy)-(C 1-3 deuteroalkylene) denotes a C 1-3 deuteroalkoxy group attached through a C 1-3 deuteroalkylene to the parent molecular moiety.
  • alkylthio refers to an alkyl group attached to the parent molecular moiety through a sulfur atom, for example, methylthio group (—SCH 3 ).
  • methylthio group —SCH 3
  • C 1-3 alkylthio denotes alkylthio groups with one to three carbon atoms.
  • fluoroalkylthio refers to a fluoroalkyl group attached to the parent molecular moiety through a sulfur atom, for example, trifluoromethylthio group (—SCF 3 ).
  • SCF 3 trifluoromethylthio group
  • C 1-3 fluoroalkylthio denotes fluoroalkylthio groups with one to three carbon atoms.
  • aryl refers to a group of atoms derived from a molecule containing aromatic ring(s) by removing one hydrogen that is bonded to the aromatic ring(s).
  • Representative examples of aryl groups include, but are not limited to, phenyl, naphthyl, indanyl, indenyl, and 1,2,3,4-tetrahydronaphth-5-yl.
  • the aryl ring may be unsubstituted or may contain one or more substituents as valence allows.
  • benzyl refers to a methyl group in which one of the hydrogen atoms is replaced by a phenyl group.
  • the phenyl ring may be unsubstituted or may contain one or more substituents as valence allows.
  • aryloxy refers to an aryl group attached through an oxygen group.
  • phenoxy refers to a phenyl group attached through an oxygen group (—O-phenyl).
  • the phenyl ring may be unsubstituted or may contain one or more substituents as valence allows.
  • heteroatom refers to oxygen (O), sulfur (S), and nitrogen (N).
  • heterocyclo or “heterocyclyl” may be used interchangeably and refer to non-aromatic 3- to 7-membered monocyclic groups and 6- to 11-membered bicyclic groups, in which at least one of the rings has at least one heteroatom (0, S or N), said heteroatom containing ring preferably having 1 to 3 heteroatoms independently selected from 0, S, and/or N.
  • Each ring of such a group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom.
  • the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
  • the fused rings completing the bicyclic group may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
  • the heterocyclo group may be attached at any available nitrogen or carbon atom.
  • the heterocyclo ring may be unsubstituted or may contain one or more substituents as valence allows.
  • Exemplary monocyclic heterocyclyl groups include oxetanyl, azetidinyl, pyrrolidinyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane, and tetrahydro-1,1-dioxothienyl.
  • Exemplary bicyclic heterocyclo groups include quinuclidiny
  • heteroaryl refers to substituted and unsubstituted aromatic 5- or 6-membered monocyclic groups and 9- or 10-membered bicyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings, said heteroatom-containing ring preferably having 1, 2, or 3 heteroatoms independently selected from O, S, and/or N.
  • Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom.
  • the fused rings completing the bicyclic group may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
  • the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
  • Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic.
  • the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring.
  • the heteroaryl ring system may be unsubstituted or may contain one or more substituents.
  • Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thiophenyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl.
  • Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridyl, dihydroisoindolyl, and tetrahydroquinolinyl.
  • heteroaryloxy refers to a heteroaryl group attached through an oxygen group to the patent molecular moiety.
  • arylalkylene refers to an aryl group attached through an alkylene group to the patent molecular moiety.
  • aryl(C 1-2 alkylene) refers to an aryl group attached through a C 1-2 alkylene to the parent molecular moiety.
  • heteroarylalkylene refers to a heteroaryl group attached through an alkylene group to the patent molecular moiety.
  • heteroaryl(C 1-2 alkylene) refers to a heteroaryl group attached through a C 1-2 alkylene to the parent molecular moiety.
  • aryloxyalkylene refers to an aryloxy group attached through an alkylene group to the patent molecular moiety.
  • aryloxy-(C 1-2 alkylene) refers to an aryloxy group attached through a C 1-2 alkylene to the parent molecular moiety.
  • heteroaryloxyalkylene refers to a heteroaryloxy group attached through an alkylene group to the patent molecular moiety.
  • heteroaryloxy-(C 1-2 alkylene) refers to a heteroaryloxy group attached through a C 1-2 alkylene to the parent molecular moiety.
  • the compounds of the present invention can be provided as amorphous solids or crystalline solids. Lyophilization can be employed to provide the compounds as amorphous solids.
  • solvates e.g., hydrates of the Compounds of the invention are also within the scope of the present invention.
  • the term “solvate” means a physical association of a compound of Formulas (I) to (VIII) with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • “Solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art.
  • compounds of Formulas (I) to (VIII), subsequent to their preparation, can be isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound of Formulas (I) to (VIII) (“substantially pure”), which is then used or formulated as described herein.
  • substantially pure compounds of Formulas (I) to (VIII) are also contemplated herein as part of the present invention.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the present invention is intended to embody stable compounds.
  • the compounds of the present invention are intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium (D) and tritium (T).
  • Isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
  • methyl (—CH 3 ) also includes deuterated methyl groups such as —CD 3 .
  • PAR4 antagonist denotes an inhibitor of platelet aggregation which binds PAR4 and inhibits PAR4 cleavage and/or signaling.
  • PAR4 activity is reduced in a dose dependent manner by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to such activity in a control cell.
  • the control cell is a cell that has not been treated with the compound.
  • PAR4 activity is determined by any standard method in the art, including those described herein (for example calcium mobilization in PAR4 expressing cells, platelet aggregation, platelet activation assays measuring e.g., calcium mobilization, P-selectin or CD40L release, or thrombosis and hemostasis models).
  • platelet activation is measured by changes in the platelet cytoplasm, by changes of the platelet membrane, by changes in the levels of analytes released by platelets, by the changes in the morphology of the platelet, by the ability of platelets to form thrombi or platelet aggregates in flowing or stirred whole blood, by the ability of platelets to adhere to a static surface which is derivatized with relevant ligands (e.g., von Willebrand Factor, collagen, fibrinogen, other extracellular matrix proteins, synthetic fragments of any of the proteins, or any combination thereof), by changes in the shape of the platelets, or any combinations thereof.
  • relevant ligands e.g., von Willebrand Factor, collagen, fibrinogen, other extracellular matrix proteins, synthetic fragments of any of the proteins, or any combination thereof.
  • platelet activation is measured by changes in the levels of one or more analytes released by platelets.
  • the one or more analytes released by platelets can be P-selectin (CD62p), CD63, ATP, or any combination thereof.
  • platelet activation is measured by the level of binding of fibrinogen or GPIIbIIIa antibodies to platelets.
  • platelet activation is measured by the degree of phosphorylation of vasodilator-stimulated phosphoprotein (VASP) upon platelet activation.
  • VASP vasodilator-stimulated phosphoprotein
  • platelet activation is measured by the level of platelet-leukocyte aggregates.
  • platelet activation is measured by proteomics profiling.
  • PAR4 antagonist also includes a compound that inhibits both PAR1 and PAR4.
  • compounds of the invention have IC 50 s in the PAR4 FLIPR Assay (described hereinafter) of about 10 ⁇ M, preferably 1 ⁇ M or less, more preferably 100 nM or less, and even more preferably 10 nM or less.
  • PAR4 FLIPR assay data for compounds of the present invention is presented in the Table.
  • the present invention provides a pharmaceutical composition, which includes a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula I-VIII, preferably, a compound selected from one of the examples, more preferably, Examples 1 to 837, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, alone or in combination with another therapeutic agent.
  • the present invention provides a pharmaceutical composition which further includes another therapeutic agent(s).
  • the present invention provides a pharmaceutical composition, wherein the additional therapeutic agent(s) are an anti-platelet agent or a combination thereof.
  • the anti-platelet agent(s) are P2Y12 antagonists and/or aspirin.
  • the P2Y12 antagonists are clopidogrel, ticagrelor, or prasugrel.
  • the present invention provides a pharmaceutical composition, wherein the additional therapeutic agent(s) are an anticoagulant or a combination thereof.
  • the anticoagulant agent(s) are a FXa inhibitor, a thrombin inhibitor, or a FXIa inhibitor.
  • the FXa inhibitors are apixaban, rivaroxaban, edoxaban, or betrixaban.
  • the thrombin inhibitor is dabigatran.
  • patient encompasses all mammalian species.
  • the term “subject” refers to any human or nonhuman organism that could potentially benefit from treatment with a PAR4 antagonist.
  • exemplary subjects include human beings of any age with risk factors for cardiovascular disease, or patients that have already experienced one episode of cardiovascular disease.
  • Common risk factors include, but are not limited to, age, male sex, hypertension, smoking or smoking history, elevation of triglycerides, elevation of total cholesterol or LDL cholesterol.
  • the subject is a species having a dual PAR1/PAR4 platelet receptor repertoire.
  • dual PAR1/PAR4 platelet receptor repertoire means that a subject expresses PAR1 and PAR4 in platelets or their precursors.
  • Exemplary subjects having a dual PAR1/PAR4 platelet receptor repertoire include human beings, non-human primates, and guinea pigs.
  • the subject is a species having a dual PAR3/PAR4 platelet receptor repertoire.
  • dual PAR3/PAR4 platelet receptor repertoire means that a subject expresses PAR3 and PAR4 in platelets or their precursors.
  • Exemplary subjects having a dual PAR3/PAR4 platelet receptor repertoire include rodents and rabbits.
  • treating cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) inhibiting the disease-state, i.e; arresting its development; and/or (b) relieving the disease-state, i.e., causing regression of the disease state.
  • “prophylaxis” or “prevention” cover the preventive treatment of a subclinical disease-state in a mammal, particularly in a human, aimed at reducing the probability of the occurrence of a clinical disease-state. Patients are selected for preventative therapy based on factors that are known to increase risk of suffering a clinical disease state compared to the general population. “Prophylaxis” therapies can be divided into (a) primary prevention and (b) secondary prevention. Primary prevention is defined as treatment in a subject that has not yet presented with a clinical disease state, whereas secondary prevention is defined as preventing a second occurrence of the same or similar clinical disease state.
  • risk reduction covers therapies that lower the incidence of development of a clinical disease state.
  • primary and secondary prevention therapies are examples of risk reduction.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination to inhibit and/or antagonize PAR4 and/or to prevent or treat the disorders listed herein. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the preventive or therapeutic effect, whether administered in combination, serially, or simultaneously.
  • thrombosis refers to formation or presence of a thrombus (pl. thrombi) within a blood vessel that may cause ischemia or infarction of tissues supplied by the vessel.
  • emblism refers to sudden blocking of an artery by a clot or foreign material that has been brought to its site of lodgment by the blood current.
  • thromboembolism refers to obstruction of a blood vessel with thrombotic material carried by the blood stream from the site of origin to plug another vessel.
  • thromboembolic disorders entails both “thrombotic” and “embolic” disorders (defined above).
  • thromboembolic disorders as used herein includes arterial cardiovascular thromboembolic disorders, venous cardiovascular or cerebrovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart or in the peripheral circulation.
  • thromboembolic disorders as used herein also includes specific disorders selected from, but not limited to, unstable angina or other acute coronary syndromes, atrial fibrillation, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the medical implants or devices include, but are not limited to: prosthetic valves, artificial valves, indwelling catheters, stents, blood oxygenators, shunts, vascular access ports, ventricular assist devices and artificial hearts or heart chambers, and vessel grafts.
  • the procedures include, but are not limited to: cardiopulmonary bypass, percutaneous coronary intervention, and hemodialysis.
  • thromboembolic disorders includes acute coronary syndrome, stroke, deep vein thrombosis, and pulmonary embolism.
  • the present invention provides a method for the treatment of a thromboembolic disorder, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis,
  • the present invention provides a method for the treatment of a thromboembolic disorder, wherein the thromboembolic disorder is selected from acute coronary syndrome, stroke, venous thrombosis, atrial fibrillation, and thrombosis resulting from medical implants and devices.
  • the present invention provides a method for the primary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease,
  • the present invention provides a method for the primary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from acute coronary syndrome, stroke, venous thrombosis, and thrombosis resulting from medical implants and devices.
  • the present invention provides a method for the secondary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, recurrent myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, recurrent myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombo
  • the present invention provides a method for the secondary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from acute coronary syndrome, stroke, atrial fibrillation and venous thrombosis.
  • stroke refers to embolic stroke or atherothrombotic stroke arising from occlusive thrombosis in the carotid communis, carotid interna, or intracerebral arteries.
  • thrombosis includes vessel occlusion (e.g., after a bypass) and reocclusion (e.g., during or after percutaneous transluminal coronary angioplasty).
  • the thromboembolic disorders may result from conditions including but not limited to atherosclerosis, surgery or surgical complications, prolonged immobilization, arterial fibrillation, congenital thrombophilia, cancer, diabetes, effects of medications or hormones, and complications of pregnancy.
  • Thromboembolic disorders are frequently associated with patients with atherosclerosis.
  • Risk factors for atherosclerosis include but are not limited to male gender, age, hypertension, lipid disorders, and diabetes mellitus. Risk factors for atherosclerosis are at the same time risk factors for complications of atherosclerosis, i.e., thromboembolic disorders.
  • Atrial fibrillation is frequently associated with thromboembolic disorders.
  • Risk factors for atrial fibrillation and subsequent thromboembolic disorders include cardiovascular disease, rheumatic heart disease, nonrheumatic mitral valve disease, hypertensive cardiovascular disease, chronic lung disease, and a variety of miscellaneous cardiac abnormalities as well as thyrotoxicosis.
  • Diabetes mellitus is frequently associated with atherosclerosis and thromboembolic disorders.
  • Risk factors for the more common type 2 include but are not limited to family history, obesity, physical inactivity, race/ethnicity, previously impaired fasting glucose or glucose tolerance test, history of gestational diabetes mellitus or delivery of a “big baby”, hypertension, low HDL cholesterol, and polycystic ovary syndrome.
  • Thrombosis has been associated with a variety of tumor types, e.g., pancreatic cancer, breast cancer, brain tumors, lung cancer, ovarian cancer, prostate cancer, gastrointestinal malignancies, and Hodgkins or non-Hodgkins lymphoma. Recent studies suggest that the frequency of cancer in patients with thrombosis reflects the frequency of a particular cancer type in the general population. (Levitan, N. et al., Medicine (Baltimore), 78(5):285-291 (1999); Levine M. et al., N Engl. J Med., 334(11):677-681 (1996); Blom, J. W.
  • VTE venous thromboembolism
  • composition means any composition, which contains at least one therapeutically or biologically active agent and is suitable for administration to the patient. Any of these formulations can be prepared by well-known and accepted methods of the art. See, for example, Gennaro, A. R., ed., Remington: The Science and Practice of Pharmacy, 20th Edition, Mack Publishing Co., Easton, Pa. (2000).
  • the invention includes administering to a subject a pharmaceutical composition that includes a compound that binds to PAR4 and inhibits PAR4 cleavage and/or signaling (referred to herein as a “PAR4 antagonist” or “therapeutic compound”).
  • a pharmaceutical composition that includes a compound that binds to PAR4 and inhibits PAR4 cleavage and/or signaling (referred to herein as a “PAR4 antagonist” or “therapeutic compound”).
  • the pharmaceutical composition is administered using methods known in the art.
  • the compound is administered orally, rectally, nasally, by inhalation, topically or parenterally, e.g., subcutaneously, intraperitoneally, intramuscularly, and intravenously.
  • the compound is optionally formulated as a component of a cocktail of therapeutic drugs to treat a thromboembolic disorder.
  • the pharmaceutical composition is administered orally.
  • a PAR4 antagonist is formulated in a capsule or a tablet for oral administration.
  • Capsules may contain any standard pharmaceutically acceptable materials such as gelatin or cellulose.
  • Tablets may be formulated in accordance with conventional procedures by compressing mixtures of a therapeutic compound with a solid carrier and a lubricant. Examples of solid carriers include starch and sugar bentonite.
  • the compound is administered in the form of a hard shell tablet or a capsule containing a binder, e.g., lactose or mannitol, a conventional filler, and a tableting agent.
  • compositions of the invention are also useful for parenteral administration, such as intravenous, subcutaneous, intramuscular, and intraperitoneal.
  • parenteral administration such as intravenous, subcutaneous, intramuscular, and intraperitoneal.
  • formulations suitable for parenteral administration include aqueous solutions of the active agent in an isotonic saline solution, a 5% glucose solution, or another standard pharmaceutically acceptable excipient.
  • Standard solubilizing agents such as PVP or cyclodextrins are also utilized as pharmaceutical excipients for delivery of the therapeutic compounds.
  • the preferred dose of the PAR4 antagonist is a biologically active dose.
  • a biologically active dose is a dose that will inhibit cleavage and/or signaling of PAR4 and have an anti-thrombotic effect.
  • the PAR4 antagonist has the ability to reduce the activity of PAR4 by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100% below untreated control levels.
  • the levels of PAR4 in platelets is measured by any method known in the art, including, for example, receptor binding assay, platelet aggregation, platelet activation assays (e.g., p-selectin expression by FACS), Western blot or ELISA analysis using PAR4 cleavage sensitive antibodies.
  • the biological activity of PAR4 is measured by assessing cellular signaling elicited by PAR4 (e.g., calcium mobilization or other second messenger assays).
  • a therapeutically effective amount of a PAR4 compound is preferably from about less than 100 mg/kg, 50 mg/kg, 10 mg/kg, 5 mg/kg, 1 mg/kg, or less than 1 mg/kg. In a more preferred embodiment, the therapeutically effective amount of the PAR4 compound is less than 5 mg/kg. In a most preferred embodiment, the therapeutically effective amount of the PAR4 compound is less than 1 mg/kg. Effective doses vary, as recognized by those skilled in the art, depending on route of administration and excipient usage.
  • the activity of the PAR4 antagonists of the present invention can be measured in a variety of in vitro assays. Exemplary assays are shown below.
  • the Fluorometric Imaging Plate Reader (FLIPR) assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention.
  • FLIPR Fluorometric Imaging Plate Reader
  • AYPGKF is a known PAR4 agonist.
  • An alternative PAR4 agonist is H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 .
  • H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 was validated as a PAR4 agonist in the FLIPR assay.
  • H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 has improved agonist activity as compared to AYPGKF with an EC 50 that is 10 fold lower than the EC 50 for AYPGKF in the FLIPR assay.
  • H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 can be synthesized using methods well known to those of skill in the art.
  • the FLIPR assay can also be used as a counterscreen to test agonist activity or PAR1 antagonist activity in a cell line that expresses both PAR1 and PAR4.
  • the PAR1 antagonist activity can be tested by the ability of the compound to inhibit calcium mobilization induced by the PAR1 agonist peptide SFLLRN or other PAR1 agonist peptides.
  • the compounds of the current invention can be tested in vitro for their ability to inhibit platelet aggregation induced by gamma-thrombin as shown below.
  • Gamma-thrombin a proteolytic product of alpha-thrombin which no longer interacts with PAR1, selectively cleaves and activates PAR4 (Soslau, G. et al., “Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib”, J. Biol. Chem., 276:21173-21183 (2001)).
  • Platelet aggregation can be monitored in a 96-well microplate aggregation assay format or using standard platelet aggregometer.
  • the aggregation assay can also be employed to test the selectivity of the compound for inhibiting platelet aggregation induced by PAR4 agonist peptides, PAR1 agonist peptide, ADP, or thromboxane analogue U46619.
  • the compounds of the current invention can be tested in vitro for their ability to inhibit platelet aggregation induced by alpha-thrombin as shown below.
  • Alpha-thrombin activates both PAR1 and PAR4.
  • the ability of a selective PAR4 antagonist of the present invention to inhibit platelet aggregation can be measured using a standard optical aggregometer.
  • the compounds of the current invention can be tested in vitro for their ability to inhibit platelet aggregation induced by tissue factor as shown below.
  • the conditions in this assay mimic the physiological events during thrombus formation.
  • platelet aggregation in human platelet rich plasma (PRP) is initiated by the addition of tissue factor and CaCl 2 .
  • Tissue factor the initiator of the extrinsic coagulation cascade, is highly elevated in human atherosclerotic plaque. Exposure of blood to tissue factor at the atherosclerotic site triggers a robust generation of thrombin and induces the formation of obstructive thrombi.
  • the activity of the PAR4 antagonists of the present invention can also be measured in a variety of in vivo assays.
  • Exemplary mammals that can provide models of thrombosis and hemostasis to test the effectiveness of the PAR4 antagonists of the present invention as antithrombotic agents include, but are not limited to, guinea pigs and primates.
  • Relevant efficacy models include, but are not limited to, electrically-induced carotid arterial thrombosis, FeCl 3 -induced carotid artery thrombosis and arteriovenous-shunt thrombosis.
  • Models of kidney bleeding time, renal bleeding time and other bleeding time measurements can be used to assess the bleeding risk of the antithrombotic agents described in the current invention.
  • SFFLRR is a known high affinity PAR1 selective agonist peptide.
  • the PAR4 agonist peptides AYPGKF and H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 were synthesized.
  • H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 showed improved PAR4 agonist activity over AYPGKF in the FLIPR assay (EC 50 value of 8 ⁇ M for H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 and 60 ⁇ M for AYPGKF) and in washed platelet aggregation assay (EC 50 value of 0.9 ⁇ M for H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 and 12 ⁇ M for AYPGKF).
  • HEK293 cells stably expressing PAR4 were generated by a standard method of transfection of human PAR4 (F2R23) cDNA expression vector and selected based on PAR4 protein expression or mRNA expression. Those cells demonstrated functional responses to PAR4 agonist peptide-induced intracellular calcium elevation using FLIPR® (Fluorometric Imaging Plate Reader; Molecular Devices Corp.). These cells also express endogenous PAR1 and can elicit calcium signal upon stimulation with PAR1 agonist peptide. Therefore, the same cells were also used to determine selectivity against PAR1 and agonist activity for both receptors. Cells from HEK293 PAR4 Clone 1.2A (BMS Arctic ID 383940) were propagated and used for calcium mobilization studies.
  • Human blood was collected in 3.8% sodium citrate at a ratio of 1 ml per 9 ml blood and centrifuged in a Sorvall® RT6000B centrifuge at 900 revolution per minute (rpm) at room temperature (RT) for 15 minutes.
  • PRP was collected and used for aggregation assay.
  • Refludan (Berlex Labs, Wayne, N.J.), a recombinant hirudin, at a final concentration of 1 unit/mL was added to the sample to selectively prevent PAR1 activation induced by residual alpha-thrombin contamination.
  • the remaining blood sample was centrifuged at 2500 rpm at room temperature for 5 minutes to collect platelet-poor plasma (PPP).
  • Human blood was collected in ACD (85 mM tri-sodium citrate, 78 mM citric acid, 110 mM D-glucose, pH 4.4) at a ratio of 1.4 ml per 10 ml blood.
  • ACD 85 mM tri-sodium citrate, 78 mM citric acid, 110 mM D-glucose, pH 4.4
  • PRP was isolated by centrifugation at 170 g for 14 minutes and platelets were further pelleted by centrifugation at 1300 g for 6 minutes. Platelets were washed once with 10 ml ACD containing 1 mg/ml bovine serum albumin.
  • Platelets were resuspended at ⁇ 2.5 ⁇ 10 8 /ml in Tyrode's Buffer (137 mM NaCl, 2 mM KCl, 1.0 mM MgCl 2 , 1 mM CaCl 2 , 5 mM glucose, 20 mM HEPES pH 7.4).
  • FLIPR-based calcium mobilization assay in HEK293 cells was used to measure PAR4 antagonism, agonism, and selectivity against PAR1.
  • the activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2 -induced intracellular calcium mobilization. Counter screens for agonist activity and PAR1 antagonist activity were also performed.
  • PAR1/PAR4-expressing HEK293 cells were grown in DMEM (Life Technology, Grand Island, N.Y.) containing 10% heat-inactivated FBS, 1% Penicillin-Streptomycin, 10 ⁇ g/mL blasticidin, and 100 ⁇ g/mL Zeocin at 37° C. with 5% CO 2 .
  • Cells were plated overnight prior to the experiment in a black 384-well Purecoat Amine clear bottom plate (Becton Dickinson Biosciences, San Jose, Calif.) at 10,000 cells/well in 30 ⁇ L growth medium and incubated in a humidified chamber at 37° C. with 5% CO 2 overnight.
  • HBSS Hank's Balanced Saline Solution
  • DMSO dimethyl sulfoxide
  • the cells were then incubated for 30 minutes at room temperature followed by addition of 20 ⁇ L of agonist peptide for antagonist activity measurement.
  • the PAR4 agonist peptide H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH 2
  • the PAR1 agonist peptide SFFLRR
  • Compound potency was derived from 11-point concentration-response curves.
  • the ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate aggregation assay format. Briefly, 90 ⁇ L of PRP or washed platelets were pre-incubated for 5 minutes at 37° C. with 3-fold serially diluted test compound, which was prepared as a 100-fold stock solution in dimethyl sulfoxide (DMSO). Aggregation was initiated by addition of 10 ⁇ L of gamma-thrombin (Haematologic Technologies, Inc. Essex Junction, Vt.) at 50-100 nM final concentration, which was titrated daily to achieve 80% platelet aggregation.
  • DMSO dimethyl sulfoxide
  • the plate was then placed into a SpectraMax® Plus Plate Reader (Molecular Devices) at 37° C. Platelet aggregation was monitored at a wavelength of 405 nm using a kinetic analysis mode. Prior to the first data collection time point, the plate was shaken for 10 seconds to allow thorough mixing. Data was subsequently collected every 10 seconds for up to 7 minutes total. Data was collected using SoftMax® 5.4.1 software and exported to Microsoft Excel for analysis. The optical density (OD) values at the time point that achieved 75% platelet activation by agonist alone were used for analysis. The OD value from a PRP sample without any treatment served as ODmaximum, and the OD value from a PPP sample containing no platelets served as the ODminimum.
  • OD optical density
  • % IPA (100-100*[ODcompound ⁇ ODminimum]/[ODmaximum ⁇ ODminimum]).
  • the aggregation assays were also employed to test the selectivity of the compound against other platelet receptors by using SFFLRR for PAR1, collagen (Chrono-Log, Havertown, Pa.) for collagen receptors, ADP for P2Y1 and P2Y12 and U46619 (Cayman Chemical, Ann Arbor, Mich.) for thromboxane receptors.
  • the ability of PAR4 antagonists to inhibit platelet aggregation induced by alpha-thrombin can be tested using human washed platelets.
  • the antagonists are pre-incubated with washed platelets for 20 min. Aggregation is initiated by addition of 1.5 nM alpha-thrombin (Haematologic Technologies, Essex Junction, Vt.) to 300 ⁇ l of washed platelets at stirring speed of 1000 rpm. Platelet aggregation is monitored using an Optical Aggregometer (Chrono-Log, Havertown, Pa.) and the area under the curve (AUC) at 6 min was measured. IC 50 values are calculated using vehicle control as 0% inhibition.
  • the ability of PAR1 or PAR4 antagonists to inhibit platelet aggregation induced by endogenous thrombin can be tested in a tissue factor driven aggregation assay. Aggregation is initiated by addition of CaCl 2 and recombinant human tissue factor, which results in the generation of thrombin through activation of the coagulation pathway in the plasma. Anticoagulant agents such as corn trypsin inhibitor (Haematologic Technologies, Essex Junction, Vt.) at 50 ⁇ g/ml and PEFABLOC® FG (Centerchem, Norwalk, Conn.) are also added to the sample to prevent fibrin clot formation during the time of the study. Platelet aggregation is monitored using standard instrumentation including optical aggregometer or impedance aggregometer.
  • the compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
  • the reaction mixtures are performed in a solvent or solvent mixture appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
  • compounds of Formula I can also be prepared from palladium catalyzed cross coupling of arylboronic acids of Formula Ib with halides R 3 —X shown in Scheme 2.
  • a regio specific synthesis of quinoxalines of Formula Ia and Ib is shown in Scheme 4.
  • a properly protected ortho-nitro aniline Ie is alkylated with methyl bromoacetate to yield compound If.
  • Deprotection of compound If and reduction of compound Ig should initiate cyclization to give rise to compound Ih.
  • Compound Ih can be oxidized to quinoxaline-2-one of Formula Ii, which can be converted to the intermediate Ij with oxophosphorus halides.
  • the halides in compound Ij can be displaced with a nucleophile containing an R 1 group to compound Ia, and compounds of Formula Ia can be converted to corresponding boronic acids of Formula Ib via Suzuki-Miyaura reaction.
  • Intermediate Ii could also be converted to Ik by condensation reaction with sodium chlorodifluoroacetate in the presence of a base such as K 2 CO 3 .
  • the difluoroalkoxy may be displaced with a nucleophile containing an R 1 group to compound Ia.
  • Compounds of Formula II of this invention can be obtained as shown in Scheme 5.
  • Compound IIa can be condensed with dicarbonyl IIb to give compound IIc.
  • Acid catalyzed cyclization provides the key bromide IId.
  • Palladium catalyzed cross coupling reaction with an appropriate boronic acid furnishes compound II.
  • Compounds of Formula IV of this invention can be obtained as shown in Scheme 7.
  • Compound IVa can be condensed with dimethylacetal IVb to give compound IVc.
  • Acid catalyzed cyclization and triflate formation provides the key coupling partner IVd.
  • Palladium catalyzed cross coupling reaction with an appropriate boronic acid furnishes the compound of Formula IV.
  • Compounds of Formula V of this invention can be obtained as shown in Scheme 8.
  • Compound Va can be condensed with acid chloride Vb to give compound Vc.
  • Acid catalyzed cyclization and carbonyl alkylation provides the key bromide Vd.
  • Palladium catalyzed cross coupling reaction with an appropriate boronic acid furnishes the compound of Formula V.
  • compounds of Formula VII can be obtained through the synthetic route shown in Scheme 10. Beginning with aryl chloride VIIa, palladium catalyzed cross coupling of various boronic acids or stannanes yields substituted anilines of structure VIIb. Nitration of compound VIIb and reduction of compound VIIc allows access to compounds of Formula VIId. Base mediated condensation of dianiline VIId with substituted bromo-ketones provides heterocycles of Formula VIIe. A final palladium-catalyzed cross coupling with aryl boronic acids or stannanes then furnishes the compounds of Formula VII.
  • Compounds of Formula VIII of this invention can be obtained by palladium catalyzed cross coupling of aryl boronic acids or stannanes with aryl chloride VIIIc as shown in Scheme 11.
  • Compound Villa can be condensed with amidines to give compound VIIIb.
  • Phosphorous oxychloride conversion of compound VIIIb to aryl chloride VIIIc followed by palladium-catalyzed cross coupling with aryl boronic acids or stannanes furnishes the compound of Formula VIII.
  • 2-halo benzothiazole XXI A synthesis of 2-halo benzothiazole XXI is shown in Scheme 12. Beginning with the appropriately substituted aniline XIX, the 2-amino benzothiazole XX is formed via addition and oxidative cyclization of a thiocyanate. Subsequent Sandmeyer chemistry is employed to generate the desired 2-halo benzothiazole XXI. With XXI in hand, various compounds of Formula I with structure XXIIa are prepared with boronic acid Ib via Suzuki cross-coupling.
  • Substitution at the 4-position of the benzothiazole R 3 group can be accomplished from intermediates XXVa and XXVb as shown in Scheme 14. Lithiation of XXVa followed by its addition to a variety of aldehydes provides XXVI, as does Grignard addition to benzaldehyde XXVb. XXVI is then coupled to Ib as described above to provide compounds of Formula I with structure XXVII.
  • chloroformate XXIX is synthesized from compounds with formulas analogous to XXVIII using phosgene. These chloroformates are then reacted with a variety of nucleophiles to generate compounds of structure XXX.
  • Compounds of structure XXXII are synthesized from amines such as XXXI using sulfonyl chloride reagents.
  • Method A PHENOMENEX® Luna C18 column (4.6 ⁇ 50 mm or 4.6 ⁇ 75 mm) eluted at 4 mL/min with 2, 4 or 8 min gradient from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% TFA; B: 10% water, 89.9% methanol, 0.1% TFA, UV 220 nm).
  • Method B PHENOMENEX® Luna C18 column (4.6 ⁇ 50 mm) eluted at 4 mL/min with a 4 min gradient from 100% A to 100% B (A: 10% acetonitrile, 89.9% water, 0.1% TFA; B: 10% water, 89.9% acetonitrile, 0.1% TFA, UV 220 nm).
  • Method C PHENOMENEX® Luna C18 column (4.6 ⁇ 50 mm or 4.6 ⁇ 75 mm) eluted at 4 mL/min with a 2, 4 or 8 min gradient from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% H 3 PO 4 ; B: 10% water, 89.9% methanol, 0.1% H 3 PO 4 , UV 220 nm).
  • Method D PHENOMENEX® Luna C18 column (4.6 ⁇ 50 mm or 4.6 ⁇ 75 mm) eluted at 4 mL/min with a 2, 4 or 8 min gradient from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% NH 4 OAc; B: 10% water, 89.9% methanol, 0.1% NH 4 OAc, UV 220 nm).
  • Method E BEH C18 2.1 ⁇ 50 mm; A: water+0.05% TFA; B: acetonitrile+0.05% TFA; wavelength 220 nm; flow rate 0.8 mL/min; 0% B to 100% B in 1 minute, gradient time 1.5 min.
  • Method F BEH C18 2.1 ⁇ 50 mm; A: water+0.05% TFA; B: acetonitrile+0.05% TFA; wavelength 220 nm; flow rate 0.8 mL/min; 0% B to 50% B in 1 minute, gradient time 1.5 min.
  • Method G BEH C18 2.1 ⁇ 50 mm; A: water+0.05% TFA; B: acetonitrile+0.05% TFA; wavelength 220 nm; flow rate 0.8 mL/min; 50% B to 100% B in 1 minute, gradient time 1.5 min.
  • Reverse phase preparative HPLC was carried out using a Shimadzu Preparative HPLC system running Discovery VP software using one of the following methods.
  • Method A PHENOMENEX® Axia Luna 5 ⁇ M C18 30 ⁇ 75 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% acetonitrile, 89.9% water, 0.1% TFA; B: 10% water, 89.9% acetonitrile, 0.1% TFA, UV 220 nm).
  • Method B YMC Sunfire 5 ⁇ M C18 30 ⁇ 100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% TFA; B: 10% water, 89.9% methanol, 0.1% TFA, UV 220 nm).
  • Method C XBridge C18, 19 ⁇ 200 mm column, 5- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Flow: 20 mL/min.
  • Method D Waters XBridge C18, 19 ⁇ 100 mm column, 5- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate; Flow: 20 mL/min.
  • Method E PHENOMENEX® Luna 5 ⁇ M C18 30 ⁇ 100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% acetonitrile, 89.9% water, 0.1% TFA; B: 10% water, 89.9% acetonitrile, 0.1% TFA, UV 220 nm).
  • Method F PHENOMENEX® Luna 5 ⁇ M C18 30 ⁇ 100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% TFA; B: 10% water, 89.9% methanol, 0.1% TFA, UV 220 nm).
  • Method G Waters XBridge C18, 19 ⁇ 200 mm, 5- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% formic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% formic acid; Flow: 20 mL/min.
  • Method A A linear gradient using solvent A (10% acetonitrile, 90% water, 0.1% of TFA) and solvent B (90% acetonitrile, 10% water, 0.1% of TFA); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min.
  • Method B A linear gradient using solvent A (10% methanol, 90% water, 0.1% of TFA) and solvent B (90% methanol, 10% water, 0.1% of TFA); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min.
  • Method C A linear gradient using solvent A (10% methanol, 90% water, 0.1% of TFA) and solvent B (90% methanol, 10% water, 0.1% of TFA); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min.
  • Method D A linear gradient using solvent A (10% methanol, 90% water, 0.1% of TFA) and solvent B (90% methanol, 10% water, 0.1% of TFA); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min.
  • Method E 30-95% acetonitrile in water with 0.1% TFA in 8 min run, Waters Xbridge 4.6 ⁇ 50 mm 5 um C18, flow rate 1.2 mL/min and UV detection was set to 220 nm.
  • the LC column was maintained at room temperature.
  • Method F 10-95% methanol in water, 0.1% TFA in a 10 min run, PHENOMENEX® Onyx Monolithic 4.6 ⁇ 100 mm 5 um C18, flow rate 2.0 mL/mL and UV detection was set to 220 nm.
  • the LC column was maintained at room temperature.
  • Method G 5-95% acetonitrile in water, 10 mM of modifier in 6 min run, Waters Xbridge 2.1 ⁇ 50 mm 5 um C18, flow rate 1.0 mL/min and UV detection was set to 220 nm.
  • the LC column was maintained at room temperature.
  • Method H BEH C18 2.1 ⁇ 50 mm; A: water+0.05% TFA; B: acetonitrile+0.05% TFA; wavelength 220 nm; flow rate 0.8 mL/min; gradient time 1.5 min; 2 to 98% B.
  • Method I BEH C18 2.1 ⁇ 50 mm; A: water+0.05% TFA; B: acetonitrile+0.05% TFA; wavelength 220 nm; flow rate 0.8 mL/min; gradient time 1.5 min; 2 to 52% B.
  • Method J BEH C18 2.1 ⁇ 50 mm; A: water+0.05% TFA; B: acetonitrile+0.05% TFA; wavelength 220 nm; flow rate 0.8 mL/min; gradient time 1.5 min; 48 to 98% B.
  • Method K Column: Waters Acquity UPLC BEH C18, 2.1 ⁇ 50 mm, 1.7- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
  • Method L Column: Waters Acquity UPLC BEH C18, 2.1 ⁇ 50 mm, 1.7- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
  • Method A Two analytical LC/MS injections were used to determine the final purity. Injection1 condition: A linear gradient using solvent A (5% acetonitrile, 95% water, 0.05% TFA) and solvent B (95% acetonitrile, 5% water, 0.05% TFA); 10-100% of solvent B over 10 min and then 100% of solvent B over 5 min.
  • Injection 2 conditions A linear gradient using solvent A (5% acetonitrile, 95% water, 0.05% TFA) and solvent B (95% acetonitrile, 5% water, 0.05% TFA); 10-100% of solvent B over 10 min and then 100% of solvent B over 5 min.
  • Method B Two analytical LC/MS injections were used to determine the final purity.
  • Injection 1 conditions Column: Waters Acquity UPLC BEH C18, 2.1 ⁇ 50 mm, 1.7- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
  • Injection 2 conditions Column: Waters Acquity UPLC BEH C18, 2.1 ⁇ 50 mm, 1.7- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
  • Procedure B To a vial containing the appropriate 5-bromopyrimidine (1.0 equiv.), palladium(II) acetate (0.1 equiv.), BINAP (0.2 equiv.), cesium carbonate (1.2 equiv.) and diphenylmethanimine (1.1 equiv.) was added toluene (0.5 M). The vial was sealed, evacuated and backfilled with Ar 3 ⁇ , and the reaction mixture was heated to 105° C. for 18 hours. The reaction mixture was then diluted with EtOAc and washed with 1M aqueous NaOH (1 ⁇ ) and brine (1 ⁇ ). The organic layer was dried with sodium sulfate, filtered and concentrated. The resulting residue was dissolved in methylene chloride before being purified by silica gel chromatography to provide the desired material.
  • Procedure C The 4-((diphenylmethylene)amino)pyrimidine intermediate (1.0 equiv.) was dissolved in 1:1 MeOH/THF (0.06M). 1M aqueous HCl (2.5 equiv.) was added to the reaction mixture at room temperature. The reaction mixture was allowed to stir at room temperature for 1 hour then diluted with water and extracted with 5:1 EtOAc/Hexanes (3 ⁇ ). The aqueous phase was concentrated and azeotroped with toluene 3 ⁇ to yield the desired 4-aminopyrimidine which was brought forward without further purification.
  • Procedure D 4-bromo-2-fluoropyridine (1.0 equiv.) was dissolved in DMF (1.1 M) along with the appropriate diol (1.5 equiv.). 60% sodium hydride in mineral oil (2.0 equiv.) was added to the reaction mixture portion-wise at 0° C. and the reaction mixture was allowed to warm to room temperature and stirred at room temperature for 4 hours. The reaction mixture was then quenched with saturated ammonium chloride solution and extracted with EtOAc (3 ⁇ ). The organic layer was washed with brine, dried with sodium sulfate, filtered and concentrated. The resulting residue was dissolved in methylene chloride before being purified by silica gel chromatography to provide the desired material.
  • Procedure E N1,N2-dimethylethane-1,2-diamine (1.0 equiv.), 2,2,2-trifluoroacetamide (2.0 equiv.), copper(I) iodide (0.2 equiv.), potassium carbonate (2.0 equiv.) and the 4-boromo-2-alkoxypyridine intermediate (1.0 equiv.) were dissolved in dioxane (0.6 M) in a sealed vial. The vial was evacuated and backfilled with Ar 3 ⁇ then the reaction mixture was stirred at 75° C. for 2 hours. 3 mL of 1:1 MeOH/H 2 O was added to the mixture which was stirred at room temperature for 2 h then at 40° C. for 1 h.
  • reaction mixture was then diluted with water and extracted with EtOAc (3 ⁇ ). The combined organic layer was washed with brine, dried with sodium sulfate, filtered and concentrated. The resulting residue was dissolved in a small amount of methylene chloride before being purified by silica gel chromatography to provide the desired material.
  • Procedure F The ester (1.0 equiv.) was dissolved in THF (0.2 M) and the solution was cooled to ⁇ 78° C. 1M DIBAL-H in toluene (3.0 equiv.) was added to the mixture which was allowed to warm to room temperature and stirred at room temperature for 30 minutes. The reaction mixture was then quenched saturated Rochelle's salt and allowed to stir for 18 h at room temperature. The mixture was then diluted with water and extracted with EtOAc (3 ⁇ ). The combined organic layer was washed with brine (1 ⁇ ), dried with sodium sulfate, filtered and concentrated yield the desired product.
  • Procedure I The alcohol (1.0 equiv.), imidazole (2.2 equiv.) and TBS-Cl (2.0 equiv.) were dissolved in THF or DCM (0.1 M). The reaction mixture was allowed to stir at room temperature for 18 h. The reaction mixture was then diluted with 1.5 M dipotassium phosphate solution and extracted with EtOAc (3 ⁇ ). The combined organic layer was washed with brine (1 ⁇ ), dried with sodium sulfate, filtered and concentrated. The resulting residue was dissolved in a small amount of methylene chloride and purified by silica gel chromatography to yield the desired product.
  • Procedure K The acetonide intermediate (1.0 equiv.) was dissolved in a mixture of 4:3:2 THF/MeOH/concentrated aqueous HCl (0.01 M), and the solution was stirred at room temperature. The resulting mixture was monitored by LCMS, and after completion of the reaction (10 min-12 hours) the mixture was diluted with EtOAc, washed with 1.5 M K 2 HPO 4 , dried over sodium sulfate, filtered, concentrated, dissolved in DMF and purified by preparative HPLC to yield the desired example.
  • the mixture was diluted with EtOAc/water, insoluble material was removed by filtration.
  • the filtrate was extracted with EtOAc, washed with brine and dried over sodium sulfate, concentrated.
  • the crude product was purified by flash chromatography (loading in chloroform, 0% to 20% dichloromethane in MeOH over 15 min using a 40 g silica gel cartridge).
  • the desired fractions were combined and concentrated and further purified by prep HPLC (method A, 10-80% B in 8 mins; with a flow rate of 40 mL/min). The desired fractions were placed in a SpeedVac overnight to remove solvent.
  • tert-butyl (2-hydroxyethyl)carbamate (3.0 g, 18.61 mmol) was dissolved in DMF (20 mL) and mixed with 4-fluoro-2-methyl-1-nitrobenzene (2.89 g, 18.61 mmol).
  • K 2 CO 3 (7.72 g, 55.8 mmol) was added. Then the mixture was stirred at 100° C. overnight. On the next day, the reaction mixture was poured into ice water (50 mL) and was extracted with EtOAc (50 mL ⁇ 2).
  • CD 3 ONa was prepared by dissolving sodium metal (60 mg, 2.500 mmol) in CD 3 OD (0.405 mL, 10 mmol) for 30 minutes.
  • Intermediate I-25B (207 mg, 0.625 mmol) was dissolved in THF (12 mL).
  • the filtrate was concentrated on a rotary evaporator and then partitioned between 150 mL of EtOAc and 30 mL of water. Next, 4M NaOH (aqueous) was added to adjust the pH to 12. The solid was filtered on a Celite pad and the filter cake was washed with EtOAc. The layers were separated and the aqueous phase was extracted twice with EtOAc. The combined organic phases were washed with saturated NaHCO 3 (aqueous), brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo to give additional product.
  • 4M NaOH aqueous
  • a microwave tube was charged with Pd 2 (dba) 3 (48.9 mg, 0.053 mmol), X-Phos (102 mg, 0.214 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (814 mg, 3.21 mmol), and potassium acetate (315 mg, 3.21 mmol).
  • the tube was capped and then evacuated and backfilled with argon 3 times.
  • Intermediate I-35K (240 mg, 1.068 mmol) in 1,4-dioxane (10 mL) was added via syringe, followed by flushing the reaction mixture with N 2 for 10 minutes. The reaction mixture was heated at 110° C.
  • Degussa grade Pd/C (1.125 g, 1.058 mmol) was added to a 250 mL round bottom flask previously purged with argon. The Pd was carefully wetted with a few milliliters of MeOH before the full amount of solvent (42.3 ml) was added. The head space of the flask was evacuated until the solvent began to slightly bubble and then back-filled 3 ⁇ with N 2 . 2,3-difluoro-1-methoxy-4-nitrobenzene (2.0 g, 10.58 mmol) was added to the black suspension, and a balloon of Hz gas was attached. The heterogeneous mixture was sparged with H 2 for 30 min, before being allowed to stir under an atmosphere of H 2 for an additional 4 h.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US16/317,248 2016-07-14 2017-07-13 Bicyclic heteroaryl substituted compounds Abandoned US20190292176A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/317,248 US20190292176A1 (en) 2016-07-14 2017-07-13 Bicyclic heteroaryl substituted compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362113P 2016-07-14 2016-07-14
US16/317,248 US20190292176A1 (en) 2016-07-14 2017-07-13 Bicyclic heteroaryl substituted compounds
PCT/US2017/041878 WO2018013774A1 (en) 2016-07-14 2017-07-13 Bicyclic heteroaryl substituted compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/041878 A-371-Of-International WO2018013774A1 (en) 2016-07-14 2017-07-13 Bicyclic heteroaryl substituted compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/123,265 Continuation US12060347B2 (en) 2016-07-14 2020-12-16 Bicyclic heteroaryl substituted compounds

Publications (1)

Publication Number Publication Date
US20190292176A1 true US20190292176A1 (en) 2019-09-26

Family

ID=59384258

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/317,248 Abandoned US20190292176A1 (en) 2016-07-14 2017-07-13 Bicyclic heteroaryl substituted compounds
US17/123,265 Active 2039-04-21 US12060347B2 (en) 2016-07-14 2020-12-16 Bicyclic heteroaryl substituted compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/123,265 Active 2039-04-21 US12060347B2 (en) 2016-07-14 2020-12-16 Bicyclic heteroaryl substituted compounds

Country Status (7)

Country Link
US (2) US20190292176A1 (https=)
EP (1) EP3484878B1 (https=)
JP (1) JP7058256B2 (https=)
KR (1) KR102460385B1 (https=)
CN (1) CN109689647B (https=)
ES (1) ES2823180T3 (https=)
WO (1) WO2018013774A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190248771A1 (en) * 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
US11932658B2 (en) 2016-07-14 2024-03-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors
WO2024131948A1 (zh) * 2022-12-22 2024-06-27 人福医药集团股份公司 制备p2x3抑制剂的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102494647B1 (ko) 2016-07-14 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물
CN109836360B (zh) * 2019-03-19 2021-08-13 南京恩泰医药科技有限公司 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物
CN113024475B (zh) * 2019-12-25 2022-08-09 宁夏大学 一种喹喔啉酮类化合物的合成方法
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
JP7753950B2 (ja) * 2022-03-30 2025-10-15 三菱ケミカル株式会社 環状亜硫酸エステルの製造方法
US20260070871A1 (en) 2022-07-28 2026-03-12 Bayer Aktiengesellschaft Process for preparation of 2-chloro-3-fluoro-4-alkoxy-anilines and 2-fluoro-3-chlorophenol
CN115925588A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钠盐的制备方法
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025032129A1 (en) 2023-08-08 2025-02-13 Syngenta Crop Protection Ag Novel aminoindane and aminotetraline compounds
US11976055B1 (en) 2023-08-24 2024-05-07 King Faisal University 2-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol as an antitumor and antimicrobial compound
US11986461B1 (en) 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound
US11964959B1 (en) 2023-09-05 2024-04-23 King Faisal University 3-(4,5-Diphenyl-2-(pyridin-3-yl)-1H-imidazol-1-yl)-N,N-dimethylpopan-1-amine as an antimicrobial compound
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
US11952361B1 (en) 2023-12-26 2024-04-09 King Faisal University 2-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl) pyridin-3-ol as an antitumor and antimicrobial compound
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052016A1 (en) * 1980-11-11 1982-05-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
WO1998020007A1 (en) * 1996-11-06 1998-05-14 Darwin Discovery Limited Quinolines and their therapeutic use
WO2016180536A1 (en) * 2015-05-13 2016-11-17 Selvita S.A. Substituted quinoxaline derivatives

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1681729A3 (ru) * 1986-07-25 1991-09-30 Берингер Ингельгейм Кг (Фирма) Способ получени производных 1,4-бензодиазепина
TW279162B (https=) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6313126B1 (en) * 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6387942B2 (en) 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
EP1348701A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
RU2007107177A (ru) 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
ZA200705872B (en) 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
WO2007149395A2 (en) 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
RU2424233C2 (ru) 2006-06-29 2011-07-20 Ф.Хоффманн-Ля Рош Аг Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
US20100305133A1 (en) 2007-11-30 2010-12-02 Smithkline Beecham Corporation Prolyl Hydroxylase Inhibitors
EA021938B1 (ru) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
GEP20125502B (en) 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
JPWO2010035745A1 (ja) * 2008-09-25 2012-02-23 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
BR112014026651A8 (pt) 2012-04-26 2018-01-16 Bristol Myers Squibb Co derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária
WO2013163244A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
LT2841437T (lt) 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
ES2929208T3 (es) 2015-02-26 2022-11-25 Univ Montreal Compuestos de imidazotiadiazol como inhibidores de PAR4
EP3262052A1 (en) 2015-02-26 2018-01-03 Bristol-Myers Squibb Company Benzothiazole and benzothiophne compounds
JP2018525371A (ja) 2015-07-30 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリール置換された二環式ヘテロアリール化合物
US10815224B2 (en) 2016-07-14 2020-10-27 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
CN109689664B (zh) 2016-07-14 2022-04-15 百时美施贵宝公司 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物
KR102494647B1 (ko) 2016-07-14 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052016A1 (en) * 1980-11-11 1982-05-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
WO1998020007A1 (en) * 1996-11-06 1998-05-14 Darwin Discovery Limited Quinolines and their therapeutic use
WO2016180536A1 (en) * 2015-05-13 2016-11-17 Selvita S.A. Substituted quinoxaline derivatives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190248771A1 (en) * 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
US10815224B2 (en) * 2016-07-14 2020-10-27 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
US11932658B2 (en) 2016-07-14 2024-03-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors
US12528827B2 (en) 2016-07-14 2026-01-20 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors
WO2024131948A1 (zh) * 2022-12-22 2024-06-27 人福医药集团股份公司 制备p2x3抑制剂的方法

Also Published As

Publication number Publication date
WO2018013774A1 (en) 2018-01-18
KR102460385B1 (ko) 2022-10-27
EP3484878A1 (en) 2019-05-22
EP3484878B1 (en) 2020-08-19
CN109689647B (zh) 2023-01-20
JP7058256B2 (ja) 2022-04-21
CN109689647A (zh) 2019-04-26
US20210163465A1 (en) 2021-06-03
KR20190027385A (ko) 2019-03-14
ES2823180T3 (es) 2021-05-06
JP2019528247A (ja) 2019-10-10
US12060347B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
US12060347B2 (en) Bicyclic heteroaryl substituted compounds
TWI589569B (zh) 絲胺酸／酥胺酸激酶抑制劑
JP6389830B2 (ja) ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法
EP3484881B1 (en) Bicyclic heteroaryl substituted compounds
US11590111B2 (en) Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
US11932658B2 (en) Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors
TWI841134B (zh) 含二氮雜亞基磺醯結構的化合物及其在醫藥上的用途
WO2024230586A1 (zh) 含二氮杂亚基磺酰结构的化合物作为pkm2激动剂的新用途
EP4721737A1 (en) Use of pharmaceutical composition comprising compound having bis(azanylylidene) sulfonyl structure for treating anemia-related diseases
OA20989A (en) Macrocyclic azolopyridine derivatives as EED and PRC2 modulators.

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE